Examining the evidence: Complementary adjunctive therapies for multiple sclerosis

Neurological Research

Volumn 30, Issue 7, 2008, Pages 710-719

  Namaka, Mike ^a   Crook, Aria ^a   Doupe, Andrea ^a   Kler, Kulwinder ^a   Vasconcelos, Marcus ^a   Klowak, Meghann ^a   Gong, Yuewen ^a   Wojewnik Smith, Alicja ^b   Melanson, Maria ^c  

^a UNIVERSITY OF MANITOBA   (Canada)

^b Dicentra Incorporate   (Canada)

^c HEALTH SCIENCES CENTRE   (Canada)

Author keywords

Autoimmune; Bee venom therapy; Herbals; Multiple sclerosis; Vitamins

Indexed keywords

BEE VENOM; CALCITRIOL; CALCIUM; CYANOCOBALAMIN; GINKGO BILOBA EXTRACT; HERBACEOUS AGENT; LOFEPRAMINE; LUTEOLIN; PHENYLALANINE; PRIMROSE OIL; THIOCTIC ACID; VITAMIN; VITAMIN D;

ALLERGIC ENCEPHALITIS; ALTERNATIVE MEDICINE; ANAPHYLAXIS; ARTICLE; DRUG MECHANISM; EVIDENCE BASED MEDICINE; HUMAN; INTERVERTEBRAL DISK HERNIA; ISCHIALGIA; MULTIPLE SCLEROSIS; NONHUMAN; VITAMIN SUPPLEMENTATION;

ANTIOXIDANTS; BEE VENOMS; CLINICAL TRIALS AS TOPIC; COMPLEMENTARY THERAPIES; DIET THERAPY; HUMANS; MULTIPLE SCLEROSIS; PLANT EXTRACTS; RISK REDUCTION BEHAVIOR; VITAMIN D;

EID: 51649101069     PISSN: 01616412     EISSN: None     Source Type: Journal    
DOI: 10.1179/174313208X325038     Document Type: Article

References (96)

1. BVT Support. Available at: http://web.archive.org/web/20011224133602/ pluto.beseen.com/boardroom/b/18675 [August 2006]
2. Health boards.com. Bee venom therapy for MS. Available at: http://www.healthboards.com/ubb/Forum84/HTML/000073.html[August 2006]
3. Ackerman KD, Heyman R, Rabin BS, et al. Stressful life events precede exacerbations of multiple sclerosis. Psychosom Med 2002; 64: 916-920
4. Altomare GF, Capella GL. "Bee sting therapy": The revival of a dangerous practice. Acta Derm Venereol 1994; 74: 409
5. Apel A, Greim B, Zettl UK. How frequently do patients with multiple sclerosis use complementary and alternative medicine? Complement Ther Med 2005; 13: 258-263
6. Beer TM, Munar M, Henner WD. A phase I trial of pulse calcitriol in patients with refractory malignancies: Pulse dosing permits substantial dose escalation. Cancer 2001; 91: 2431-2439
7. Bertolotto A, Capobianco M, Malucchi S, et al. Transforming growth factor beta1 (TGFbeta1) mRNA level correlates with magnetic resonance imaging disease activity in multiple sclerosis patients. Neurosci Lett 1999; 263: 21-24
8. Bizzozero OA, DeJesus G, Callahan K, et al. Elevated protein carbonylation in the brain white matter and gray matter of patients with multiple sclerosis. J Neurosci Res 2005; 81: 687-695
9. 2-activating protein induces the synthesis of IL-1 and TNF in human monocytes. J Immunol 1995; 154: 4027-4031
10. Bowling AC. Alternative Medicine in Multiple Sclerosis, New York: Demos Medical Publishing Inc., 2001
11. Buljevac D, Hop WC, Reedeker W, et al. Self reported stressful life events and exacerbations in multiple sclerosis: Prospective study. BMJ 2003; 327: 646
12. Caldis-Coutris N, Namaka M, Melanson M. Nutritional management of multiple sclerosis. CPJ/RPC 2002; 135: 31-40
13. Cantorna MT, Humpal-Winter J, DeLuca HF. Dietary calcium is a major factor in 1,25-dihydroxycholecalciferol suppression of experimental autoimmune encephalomyelitis in mice. J Nutr 1999; 129: 1966-1971
14. Cerrato PL. A therapeutic bee sting? RN 1998; 61: 57-58
15. Clerici M, Saresella M, Trabattoni D, et al. Single-cell analysis of cytokine production shows different immune profiles in multiple sclerosis patients with active or quiescent disease. J Neuroimmunol 2001; 121: 88-101
16. Cosman F, Nieves J, Komar L, et al. Fracture history and bone loss in patients with MS. Neurology 1998; 51: 1161-1165
17. Crawford MA, Budowski P, Hassam AG. Dietary management in multiple sclerosis. Proc Nutr Soc 1979; 38: 373-389
18. DiPiro J, Talbert R, Yee G. Multiple sclerosis. In: Pharmacotherapy: A Pathophysiologic Approach, New York: McGraw-Hill Medical, 2002: pp. 1019-1022
19. Eisenberg DM, Davis RB, Ettner SL, et al. Trends in alternative medicine use in the United States, 1990-1997: Results of a follow-up national survey. JAMA 1998; 280: 1569-1575
20. Esparza ML, Sasaki S, Kesteloot H. Nutrition, latitude, and multiple sclerosis mortality: An ecologic study. Am J Epidemiol 1995; 142: 733-737
21. Gallai V, Sarchielli P, Trequattrini A, et al. Cytokine secretion and eicosanoid production in the peripheral blood mononuclear cells of MS patients undergoing dietary supplementation with n-3 polyunsaturated fatty acids. J Neuroimmunol 1995; 56: 143-153
22. Garcion E, Wion-Barbot N, Montero-Menei CN, et al. New clues about vitamin D functions in the nervous system. Trends Endocrinol Metab 2002; 13: 100-105
23. Gillissen A, Nowak D. Characterization of N-acetylcysteine and ambroxol in anti-oxidant therapy. Respir Med 1998; 92: 609-623
24. Giuliani F, Goodyer CG, Antel JP, et al. Vulnerability of human neurons to T cell-mediated cytotoxicity. J Immunol 2003; 171: 368-379
25. Goodin DS, Frohman EM, Garmany GP, Jr, et al. Disease modifying therapies in multiple sclerosis: Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines. Neurology 2002; 58: 169-178
26. Gross C, Stamey T, Hancock S, et al. Treatment of early recurrent prostate cancer with 1,25-dihydroxyvitamin D3 (calcitriol). J Urol 1998; 159: 2035-2059
27. Hamedani M, Vatanpour H, Saadat F, et al. Bee venom, immunostimulant or immunosuppressor? Insight into the effect on matrix metalloproteinases and interferons. Immunopharmacol Immunotoxicol 2005; 27: 671-681
28. Hauser R, Daugio M, Wester D. Bee venom therapy for treating multiple sclerosis: A clinical trial. Altern Complement Ther 2001; 7: 37-45
29. Hayes CE, Cantorna MT, DeLuca HF. Vitamin D and multiple sclerosis. Proc Soc Exp Biol Med 1997; 216: 21-27
30. Heaney RP, Dowell MS, Hale CA, et al. Calcium absorption varies within the reference range for serum 25-hydroxyvitamin D. J Am Coll Nutr 2003; 22: 142-146
31. Heinrich M, Barnes J, Gibbons, S. et al. Fundamentals of Pharmacotherapy and Phytotherapy, Oxford: Churchill Livingstone, 2004: pp. 67, 270-271.
32. HendriksJJ, de Vries HE, van der Pol SM, et al. Flavonoids inhibit myelin phagocytosis by macrophages: A structure-activity relationship study. Biochem Pharmacol 2003; 65: 877-885
33. 3 metabolically active in the intestine. Proc Natl Acad Sci USA 1971; 68: 803-804
34. Hougee S, Sanders A, Faber J, et al. Decreased pro-inflammatory cytokine production by LPS-stimulated PBMC upon in vitro incubation with the flavonoids apigenin, luteolin or chrysin, due to selective elimination of monocytes/macrophages. Biochem Pharmacol 2005; 69: 241-248
35. Hvas AM, Nexo E. Holotranscobalamin - a first choice assay for diagnosing early vitamin B deficiency? J Intern Med 2005; 257: 289-298
36. Johnson SK, Diamond BJ, Rausch S, et al. The effect of ginkgo biloba on functional measures in multiple sclerosis: A pilot randomized controlled trial. Explore (NY) 2006; 2: 19-24.
37. 2 plays a key role in the pathogenesis of multiple sclerosis-like disease. Neuron 2004; 41: 323-335
38. Killestein J, Den Drijver BF, van der Graaff WL, et al. Intracellular cytokine profile in T-cell subsets of multiple sclerosis patients: Different features in primary progressive disease. Mult Scler 2001; 7: 145-150
39. Kim HW, Kwon YB, Ham TW, et al. General pharmacological profiles of bee venom and its water soluble fractions in rodent models. J Vet Sci 2004; 5: 309-318
40. Korwin-Piotrowska T, Nocon D, Stankowska-Chomicz A, et al. Experience of PADMA 28 in multiple sclerosis. Phytother Res 1992; 6: 133-136
41. Kuzminski AM, del Giacco EJ, Allen RH, et al. Effective treatment of cobalamin deficiency with oral cobalamin. Blood 1998; 92: 1191-1198
42. Kwon YB, Lee HJ, Han HJ, et al. The water-soluble fraction of bee venom produces antinociceptive and anti-inflammatory effects on rheumatoid arthritis in rats. Life Sci 2002; 71: 191-204
43. Kwon YB, Lee JD, Lee HJ, et al. Bee venom injection into an acupuncture point reduces arthritis associated edema and nociceptive responses. Pain 2001; 90: 271-280
44. Lauer K. Diet and multiple sclerosis. Neurology 1 997; 49: S55-S61
45. Lee JD, Kim SY, Kim TW, et al. Anti-inflammatory effect of bee venom on type II collagen-induced arthritis. Am J Chin Med 2004; 32: 361-367
46. Lemire JM, Archer DC. 1,25-dihydroxyvitamin D3 prevents the in vivo induction of murine experimental autoimmune encephalomyelitis. J Clin Invest 1991; 87: 1103-1107
47. Loder C, Allawi J, Horrobin DF. Treatment of multiple sclerosis with lofepramine, L-phenylalanine and vitamin B(12): Mechanism of action and clinical importance: Roles of the locus coeruleus and central noradrenergic systems. Med Hypotheses 2002; 59: 594-602
48. Mahon BD, Gordon SA, Cruz J, et al. Cytokine profile in patients with multiple sclerosis following vitamin D supplementation. J Neuroimmunol 2003; 134: 128-132
49. Marracci GH, Jones RE, McKeon GP, et al. Alpha lipoic acid inhibits T cell migration into the spinal cord and suppresses and treats experimental autoimmune encephalomyelitis. J Neuroimmunol 2002; 131: 104-114
50. Marracci GH, McKeon GP, Marquardt WE, et al. Alpha lipoic acid inhibits human T-cell migration: Implications for multiple sclerosis. J Neurosci Res 2004; 78: 362-370
51. Martino G, Grohovaz F, Brambilla E, et al. Proinflammatory cytokines regulate antigen-independent T-cell activation by two separate calcium-signaling pathways in multiple sclerosis patients. Ann Neurol 1998; 43: 340-349
52. Martino G, Hartung HP. Immunopathogenesis of multiple sclerosis: The role of T cells. Curr Opin Neurol 1999; 12: 309-321
53. 2 alpha-deficient mice are resistant to experimental autoimmune encephalomyelitis. J Exp Med 2005; 202: 841-851
54. Mathieu C, van Etten E, Gysemans C, et al. In vitro and in vivo analysis of the immune system of vitamin D receptor knockout mice. J Bone Miner Res 2001; 16: 2057-2065
55. Mohr DC, Goodkin DE, Bacchetti P, et al. Psychological stress and the subsequent appearance of new brain MRI lesions in MS. Neurology 2000; 55: 55-61
56. Mohr DC, Hart SL, Julian L, et al. Association between stressful life events and exacerbation in multiple sclerosis: A meta-analysis. BAJ 2004; 328: 731
57. Morini M, Roccatagliata L, Dell'Eva R, et al. Alpha-lipoic acid is effective in prevention and treatment of experimental autoimmune encephalomyelitis. J Neuroimmunol 2004; 148: 146-153
58. Munger KL, Zhang SM, O'Reilly E, et al. Vitamin D intake and incidence of multiple sclerosis. Neurology 2004; 62: 60-65
59. Nayak S, Matheis RJ, Schoenberger NE, et al. Use of unconventional therapies by individuals with multiple sclerosis. Clin Rehabil 2003; 17: 181-191
60. Nelson DA. Dorsal root ganglia may be reservoirs of viral infection in multiple sclerosis. Med Hypotheses 1993; 40: 278-283
61. Nieves J, Cosman F, Herbert J, et al. High prevalence of vitamin D deficiency and reduced bone mass in multiple sclerosis. Neurology 1994; 44: 1687-1692
62. Nordvik I, Myhr KM, Nyland H, et al. Effect of dietary advice and n-3 supplementation in newly diagnosed MS patients. Acta Neurol Scand 2000; 102: 143-149.
63. Noseworthy JH, Lucchinetti C, Rodriguez M, et al. Multiple sclerosis. N Engl J Med 2000; 343: 938-952
64. Novella S. The new England skeptical society: Bee venom therapy. Available at: http://www.theness.com/articles.asp?id=9[August 2006]
65. Oken BS, Kishiyama S, Zajdel D, et al. Randomized controlled trial of yoga and exercise in multiple sclerosis. Neurology 2004; 62: 2058-2064
66. Ozenci V, Kouwenhoven M, Link H. Cytokines in multiple sclerosis: Methodological aspects and pathogenic implications. Mult Scler 2002; 8: 396-404
67. 2-released arachi-donic acid. Free Radio Biol Med 2004; 36: 319-329
68. Payne A. Nutrition and diet in the clinical management of multiple sclerosis. J Hum Nutr Diet 2001; 14: 349-357
69. Reynolds EH. Multiple sclerosis and vitamin B12 metabolism. J Neuroimmunol 1992; 40: 225-230
70. Riise T, Moen BE, Kyvik KR. Organic solvents and the risk of multiple sclerosis. Epidemiology 2002; 13: 718-720
71. Romberg A, Virtanen A, Ruutiainen J. Long-term exercise improves functional impairment but not quality of life in multiple sclerosis. J Neurol 2005; 252: 839-845
72. Romberg A, Virtanen A, Ruutiainen J, et al. Effects of a 6-month exercise program on patients with multiple sclerosis: A randomized study. Neurology 2004; 63: 2034-2038
73. Sadovnick AD, Yee IM, Ebers GC, et al. Factors influencing sib risks for multiple sclerosis. Clin Genet 2000; 58: 431-435
74. 2 and inhibits its enzymatic activity. Biochem Biophys Res Commun 1997; 238: 436-442
75. 12 and its relationship to age of onset of multiple sclerosis. Int I Neurosci 1993; 71: 93-99
76. Schiffer RB, McDermott MP, Copley C. A multiple sclerosis cluster associated with a small, north-central Illinois community. Arch Environ Health 2001; 56: 389-395
77. Smith DC, Johnson CS, Freeman CC, et al. A phase I trial of calcitriol (1,25-dihydroxycholecalciferol) in patients with advanced malignancy. Clin Cancer Res 1999; 5: 1339-1345
78. Smith KJ, Lassmann H. The role of nitric oxide in multiple sclerosis. Lancet Neurol 2002; 1: 232-241
79. Somerfield SD. Bee venom and arthritis: Magic, myth or medicine? N Z Med J 1986; 99: 281-283
80. 2- production. Inflammation 1986; 10: 175-182
81. Swank RL, Dugan BB. Effect of low saturated fat diet in early and late cases of multiple sclerosis. Lancet 1 990; 336: 37-39
82. The American Apitherapy Society. Available at: http://www.a-pitherapy. org/news.htmI [August 2006]
83. van den Berg M, Dawes H, Wade DT, et al. Treadmill training for individuals with multiple sclerosis: A pilot randomised trial. J Neurol Neurosurg Psychiatry 2006; 77: 531-533
84. van der Goes A, Brouwer J, Hoekstra K, et al. Reactive oxygen species are required for the phagocytosis of myelin by macrophages. J Neuroimmunol 1998; 92: 67-75
85. van der Mei IA, Ponsonby AL, Dwyer T, et al. Past exposure to sun, skin phenotype, and risk of multiple sclerosis: Case-control study. BMJ 2003; 327: 316
86. van Meeteren ME, Teunissen CE, Dijkstra CD, et al. Antioxidants and polyunsaturated fatty acids in multiple sclerosis. Eur J Clin Nutr 2005; 59: 1347-1361
87. Verbeek R, Plomp AC, van Tol EA, et al. The flavones luteolin and apigenin inhibit in vitro antigen-specific proliferation and inter-feron-gamma production by murine and human autoimmune T cells. Biochem Pharmacol 2004; 68: 621-629
88. Vieth R. Vitamin D supplementation, 25-hydroxyvitamin D concentrations, and safety. Am J Clin Nutr 1999; 69: 842-856
89. Vieth R, Fraser D. Vitamin D insufficiency: No recommended dietary allowance exists for this nutrient. CMAJ 2002; 166: 1541-1542
90. Wade DT, Young CA, Chaudhuri KR, et al. A randomised placebo controlled exploratory study of vitamin B-12, lofepramine, and L-phenylalanine (the 'cari loder regime') in the treatment of multiple sclerosis. J Neurol Neurosurg Psychiatry 2002; 73: 246-249
91. 3 synthesis in human skin. J Clin Endocrinol Metab 1988; 67: 373-378
92. Weinstock-Guttman B, Baier M, Park Y, et al. Low fat dietary intervention with omega-3 fatty acid supplementation in multiple sclerosis patients. Prostaglandins Leukot Essent Fatty Acids 2005; 73: 397-404
93. Welch GN, Loscalzo J. Homocysteine and atherothrombosis. N Engl J Med 1 998; 338: 1042-1050
94. Wesselius T, Heersema DJ, Mostert JP, et al. A randomized crossover study of bee sting therapy for multiple sclerosis. Neurology 2005; 65: 1764-1768
95. Yadav V, Marracci G, Lovera J, et al. Lipoic acid in multiple sclerosis: A pilot study. Mult Scler 2005; 11: 159-165
96. Yoirish N. The Curative Properties of Honey and Bee Venom, San Francisco, CA: New Glide Publications, 1977